Get access

Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2

Authors


  • In the past year, Dr Yasuhito Tanaka has consulted to MSD K.K., and Chugai Pharmaceutical Co., Ltd. and has received research funding from grants from MSD K.K and Chugai Pharmaceutical Co., Ltd. Dr Norifumi Kawada has consulted to MSD K.K and Chugai Pharmaceutical Co., Ltd. and has received research funding from grants from MSD K.K and Chugai Pharmaceutical Co., Ltd. Dr Akihiro Tamori has received consulting and lecture fees from MSD K.K and Chugai Pharmaceutical Co., Ltd. Masaru Enomoto has received consulting and lecture fees from MSD K.K and Chugai Pharmaceutical Co., Ltd.

  • The other authors report no conflicts of interest.

Dr Akihiro Tamori, Department of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. Email: atamori@med.osaka-cu.ac.jp

Abstract

Aim:  We evaluated the efficacy of response-guided therapy in patients with hepatitis C virus (HCV) genotype 2.

Methods:  We studied 105 patients with an HCV genotype 2 load of higher than 5.0 Log IU/mL who received more than 75% of the target dose of pegylated interferon plus ribavirin. Among patients with rapid viral response (RVR; no HCV RNA detected at week 4), 14 selected 16 weeks of therapy (group A), and 28 selected 24 weeks of therapy (group B). Among non-RVR patients, 40 selected 24 weeks of therapy (group C), and 19 selected 48 weeks of therapy (group D).

Results:  All patients in group A and B achieved a sustained viral response (SVR). Clinical characteristics did not differ significantly between groups C and D. However, the proportion of patients in whom HCV RNA disappeared at a later week after starting treatment was higher in group D (P = 0.0578). SVR rate was 73% in C, and 79% in D. Among patients in whom HCV RNA disappeared between weeks 5 and 8, SVR was achieved in 28 (82%) of 34 patients in C and 10 (91%) of 11 patients in D. Among patients whose HCV RNA disappeared between weeks 9 and 12, SVR was achieved in one (20%) of five patients in C and five (63%) of eight patients in D (not statistically significant).

Conclusions:  16 weeks of combination therapy could achieve an adequate antiviral effect for RVR patients. Extending therapy could not significantly improve SVR rate in non-RVR patients.

Ancillary